SWITCHED ON
The daily technology series nobody asked for but everyone needed
Forever Is a Long Time: The Anti-Aging Technology Reckoning
The science of why we age is further along than most people realise. The science of what to do about it is considerably more contested than its investors would like to admit.
Death has been the one problem that every civilisation, every religion, and every sufficiently wealthy individual has eventually tried to solve. Silicon Valley is simply the first to approach it with a venture capital term sheet.
Yesterday we went inside the skull — brain-computer interfaces, Neuralink, paralysed patients moving cursors with thought, and the deeply underexplored question of what neural privacy law looks like when the data being harvested is the electrical record of your own cognition. Today we are staying biological but zooming out to the largest possible frame: the question of whether the human lifespan is a fixed parameter or an engineering problem. Anti-aging technology. Longevity science. The field that attracts more billionaire funding, more breathless press coverage, more genuine scientific activity, and more outright charlatanism per square metre than almost any other in existence. Let's try to work out what's real.
We should start with the biology, because the biology is actually more interesting than the supplement stacks and blood transfusion protocols that tend to dominate the coverage.
01 — Why We Age: The Actual Science
Aging is not a single process. This is the first thing to understand and the thing that makes the field genuinely difficult. It is the cumulative result of multiple overlapping biological mechanisms that interact with each other in ways that are still being mapped. The hallmarks of aging — a framework developed by researchers López-Otín, Blasco, Partridge, Serrano, and Kroemer, updated most recently in 2023 — identifies twelve distinct processes that contribute to aging at the cellular and molecular level.
Genomic instability: the accumulation of DNA damage over time as repair mechanisms become less efficient. Telomere attrition: the gradual shortening of the protective caps on chromosomes with each cell division, until the cell can no longer divide and enters senescence. Epigenetic alterations: changes to the patterns of gene expression that accumulate over time and shift cells away from their optimal function. Loss of proteostasis: the declining ability of cells to manage the quality of their proteins, leading to the accumulation of misfolded proteins associated with diseases including Alzheimer's and Parkinson's. Disabled macroautophagy: the decline in the cell's housekeeping mechanisms for clearing damaged components. Deregulated nutrient sensing: changes in the pathways that regulate metabolism and cellular response to nutrient availability. Mitochondrial dysfunction: the declining efficiency of the cellular machinery that produces energy. Cellular senescence: the accumulation of cells that have stopped dividing but remain metabolically active and secrete inflammatory signals that damage surrounding tissue. Stem cell exhaustion: the declining capacity of stem cell populations to replenish and repair tissues. Altered intercellular communication: changes in the signalling between cells that contribute to chronic inflammation and tissue dysfunction. Chronic inflammation: a low-grade inflammatory state that drives multiple age-related diseases. Dysbiosis: changes in the composition of the gut microbiome that affect systemic health.
Twelve mechanisms. Most anti-aging interventions currently being studied or sold target one or at most a few of them. The challenge of addressing aging comprehensively is the challenge of addressing all twelve simultaneously without the interventions for one mechanism making others worse.
02 — What the Serious Science Has Found
The most robust finding in longevity research, replicated across species from yeast to mice to primates, is that caloric restriction — eating significantly less than ad libitum — extends healthy lifespan. The effect is consistent and substantial in animal models. The human data is more limited and more complicated, because running a decades-long caloric restriction study in humans is extremely difficult, and because the relationship between caloric restriction's effects and human longevity is not straightforwardly linear.
Rapamycin, a drug originally developed as an immunosuppressant for organ transplant patients, has shown the most consistent lifespan-extending effects of any drug tested in mammals to date. It works by inhibiting a protein called mTOR, a central regulator of cell growth and metabolism that also happens to be a key mediator of the nutrient-sensing pathway that caloric restriction affects. Rapamycin extends lifespan in mice even when started in late middle age — a finding that generated considerable excitement because it suggested the aging process could be meaningfully altered after it was well underway. It is already being used off-label by a significant number of longevity-oriented physicians and biohackers. The long-term safety profile in healthy humans is unknown. mTOR inhibition affects immune function. The risks of taking an immunosuppressant long-term without clinical indication are not trivial.
The gap between "this extends lifespan in mice" and "this is safe and effective for humans" is one of the most consistently underestimated distances in the history of medicine.
Senolytics — drugs that selectively clear senescent cells from tissues — are another area of genuine scientific interest backed by compelling animal data. The accumulation of senescent cells is a meaningful driver of age-related tissue dysfunction. Clearing them in aged mice improves physical function, reduces inflammation, and extends healthy lifespan. Human trials are underway for specific conditions including idiopathic pulmonary fibrosis and diabetic kidney disease. The results so far are mixed and modest. The leap from treating specific diseases to extending healthy human lifespan is not yet supported by clinical evidence.
03 — The Billionaire Biohacker Problem
Bryan Johnson is a tech entrepreneur who sold his company Braintree to PayPal for $800 million and subsequently devoted a significant portion of his net worth and essentially all of his waking attention to not dying. His Project Blueprint protocol involves a highly restrictive diet, approximately 111 supplements daily, continuous biological monitoring, regular infusions of plasma from his own teenage son, and a team of around thirty doctors tracking dozens of biomarkers. He claims his biological age is decades younger than his chronological age. He publishes his protocols and data publicly.
Johnson is, depending on your perspective, a visionary pioneer demonstrating what rigorous self-experimentation can achieve, or a deeply strange illustration of what happens when a very wealthy person with significant anxiety about mortality gains access to an industry that is extremely good at selling him things. Possibly both. What he is not is a clinical trial. N=1 self-experiments conducted without controls by individuals with enormous financial and psychological investment in particular outcomes do not produce reliable scientific evidence, regardless of how many data points are collected.
Jeff Bezos has backed Altos Labs, a cellular reprogramming company working on resetting the epigenetic age of cells — essentially returning aged cells to a younger state using techniques derived from the Nobel Prize-winning work of Shinya Yamanaka. The science underlying cellular reprogramming is real and significant. Altos Labs has attracted serious researchers. The gap between the laboratory results and a clinical intervention that safely extends healthy human lifespan remains substantial. The company has raised billions. It has not yet published human results.
Google co-founder Larry Page backed Calico, a longevity company launched in 2013 with a $1.5 billion commitment from Google and AbbVie. Calico has operated largely in stealth for over a decade. Its published output has been modest relative to its funding. This is not necessarily damning — serious basic science takes time — but it is not the trajectory of a project that has found transformative answers.
04 — What Is Actually Being Sold
The longevity supplement market is enormous, growing rapidly, and almost entirely unregulated in the sense that matters. Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), precursors to NAD+ which declines with age, are sold widely on the basis of animal studies showing metabolic and longevity benefits. Human trials exist but are small and short, measuring biomarkers rather than health outcomes. Resveratrol, the compound in red wine that generated enormous excitement in the 2000s following David Sinclair's mouse studies, has produced consistently disappointing results in human trials. Metformin, the diabetes drug being studied for lifespan extension in the TAME trial, has more supporting evidence than most but remains unproven for this purpose in healthy populations.
The longevity clinic sector — offering comprehensive biomarker testing, personalised protocols, and supervised access to drugs like rapamycin and peptides like BPC-157 — has grown substantially. These clinics operate in regulatory grey zones, typically by framing interventions as wellness rather than medicine. The practitioners range from serious physicians conducting careful medicine to opportunists selling expensive placebos with bloodwork attached. Telling the difference requires more due diligence than most clients perform.
The longevity industry has correctly identified that people will pay extraordinary amounts of money to feel they are doing something about aging. It has been less rigorous about ensuring that the things it sells actually work.
05 — The Question Nobody Wants to Ask
Assume, for a moment, that the science works. Assume that meaningful human lifespan extension becomes achievable — not immortality, but an additional thirty or fifty healthy years for those who can access the interventions. What does that world look like?
The optimistic framing is obvious: more time, more experience, more contribution, the accumulated wisdom of longer lives applied to the problems of a longer future. The less examined questions are harder. Who can afford it? If lifespan extension is expensive — and it will be, at least initially — it becomes another dimension along which inequality compounds. The wealthy already live longer than the poor by substantial margins in every country on earth. A technology that extends the lifespans of the already-long-lived while remaining inaccessible to those dying young from preventable diseases is not straightforwardly a good outcome for humanity.
What happens to social structures designed around the assumption that people die? Pension systems. Inheritance patterns. Political representation, in a world where voters who have been alive for a hundred and fifty years have different priorities than voters who have been alive for thirty. Career structures, in a world where a single person occupies a senior role for eighty years instead of twenty. The assumption of generational turnover is embedded in almost every institution we have built. Removing it without redesigning those institutions is not a neutral act.
These questions are not arguments against longevity research. They are arguments for treating it as the civilisational-scale intervention it would be, rather than a consumer product to be sold to people who can afford the subscription.
Tomorrow we are moving from the body to the lab — specifically to the question of what happens when you grow organs outside a human being entirely. Lab-grown organs and 3D bioprinting: the state of the science, what has been transplanted into humans, what is still years away, and whether the waiting list for a kidney transplant might one day be a solvable problem rather than a permanent tragedy. See you then.
Switched On is a daily technology series covering AI, social media, data privacy, and the digital forces reshaping modern life — with no corporate spin, no false comfort, and absolutely no mercy for buzzwords.
